Finch Therapeutics Group, Inc. (FNCH)

NASDAQ: FNCH · IEX Real-Time Price · USD
2.57
-0.14 (-5.17%)
Jul 7, 2022 10:24 AM EDT - Market open

Company Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.

The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease.

The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota.

Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Finch Therapeutics Group, Inc.
Country United States
Founded 2017
IPO Date Mar 19, 2021
Industry Biotechnology
Sector Health Care
Employees 189

Contact Details

Address:
200 Inner Belt Road
Somerville, MA 02143
United States
Phone 617 229 6499
Website finchtherapeutics.com

Stock Details

Ticker Symbol FNCH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $17.00
CIK Code 1733257
ISIN Number US31773D1019
SIC Code 2836

Key Executives

Name Position
Dr. Mark Burnham Smith Ph.D. Chief Executive Officer and Director
Marc B. Blaustein C.F.A., CFA, MPP Chief Operating Officer, Principal Financial and Accounting Officer
Joseph D. Vittiglio Esq., J.D. Chief Business and Legal Officer and Corporate Secretary
Bryan Gillis M.B.A. Chief Technology Officer
James S. Sigler Executive Vice President of CMC
Sonia Timberlake Senior Vice President of Research
Dr. Michelle L. Rose Chief Regulatory Officer
Dr. Howard Franklin M.B.A., M.D. Interim Chief Medical Officer
Dr. Alka Batycky Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Jun 16, 2022 8-K Current report
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities